This is an interesting review of a snapshot of FAERS data, notes continuation and (most importantly) emergence after use, and that the symptoms are way out of the bounds of reported AEs from the previous controlled studies. This will be useful for our cause, and goes to show how important it is that you report your case of PFS in detail to your national pharmaceutical watchdogs, such as the FAERS in the US or the MHRA Yellow card scheme in the UK. Details for local reporting are on the foundation website.
2 Likes